RxDoctor Payments Data

Jerry Banks, MD

Internal Medicine · Mobile, ALNPI 1205179504

Payments from drug & device makers

$700in general payments, 2019–2025

Across 43 payments — averaging $16.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$147
  • AbbVie$146
  • Boehringer Ingelheim$84
  • GSK$71
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$66
  • Sanofi Pasteur Inc.$42
  • plus $145 from 7 others

What the payments were for

  • Food & beverage$700100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$700 in reported general payments places this provider in the 55th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$183,705
Medicare patients
430
Services billed
6,006

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide84$90,487
JardianceEmpagliflozin91$77,761
EliquisApixaban65$50,159
RybelsusSemaglutide29$35,102
MounjaroTirzepatide31$32,406
FarxigaDapagliflozin Propanediol30$25,873
EntrestoSacubitril/Valsartan20$24,364
XareltoRivaroxaban22$19,285
LinzessLinaclotide25$18,299
Breztri AerosphereBudesonide/Glycopyr/Formoterol20$15,880
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$14,878
MyrbetriqMirabegron12$8,863
Breo ElliptaFluticasone/Vilanterol11$7,425
SavellaMilnacipran Hcl12$4,732
Humalog Kwikpen U-100Insulin Lispro31$3,842

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$24$125,589113 claims
Boehringer IngelheimJardiance$84$77,76191 claims
PfizerEliquis$16$50,15965 claims
AstraZenecaFarxiga, Breztri Aerosphere$18$41,75350 claims
Lilly USA, LLCMounjaro$36$32,40631 claims
AbbVieLinzess, Savella$146$23,03237 claims
GSKTrelegy Ellipta, Breo Ellipta$71$22,30332 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →